Version: 1.0.0 | Published: 8 Oct 2024 | Updated: 228 days ago
Documentation
Description:
TNT is a phase III, multi centre, randomised trial of carboplatin versus docetaxel in women with ER-, PgR- and HER2- metastatic or recurrent locally advanced breast cancer. Patients will be randomised (1:1) to carboplatin or docetaxel and will cross over to the alternative treatment (docetaxel (if randomised to carboplatin) or carboplatin (if randomised to docetaxel)) on progression. Trial Treatment: Group A: Carboplatin AUC 6, q 3 weeks for 6 cycles (18 weeks) Group B: Docetaxel 100mg/m2, q 3 weeks for 6 cycles (18 weeks) On evidence of disease progression, patients will cross over to the alternative treatment.
Coverage
Spatial:
United Kingdom,England
Provenance
Temporal
Start Date:
01 January 2007
Time Lag:
Variable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided
Access Request Cost:
Not specified
Delivery Lead Time:
Not applicable
Data Controller:
The Institute of Cancer Research
Usage
Resource Creators:
In Progress
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Languages:
en
Formats:
In Progress